The European Union OK’d Mavenclad back in August. Now, Canada has come on board with approval for this oral MS therapy, which has been reporting very good success at attacking MS. How about the United States joining them? Apparently, it won’t happen anytime soon. The drug manufacturer hasn’t even applied, yet, for approval in the States.
Canadians with relapsing-remitting multiple sclerosis (RRMS) can now receive Merck’s Mavenclad (cladribine tablets), now that Health Canada has approved Mavenclad as a therapy to reduce the frequency of MS exacerbations and delay disease progression.
Merck expects the drug to be commercially available by early January 2018 throughout Canada, which has the world’s highest MS rate.
The news can’t always be positive about MS DMDs. In this case, Phase-2 trials of Laquinimod failed to mirror the success that was reported in animal trials.
Sweden’s Active Biotech said its experimental therapy Laquinimod failed to meet the primary and secondary objectives of a Phase 2 clinical trial evaluating the drug’s potential to treat primary progressive multiple sclerosis (PPMS).
This study is reporting what appears to be a trifecta for MS patients who use steroids: less cost, less hassle and results that are the same with a pill as they are with an IV. Now, if scientists could only develop steroids that have no side effects.
Oral steroids may be cheaper, more convenient and less invasive alternatives than intravenous steroids in treating relapses in multiple sclerosis (MS) patients, suggests an analysis of five randomized trials.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?